文献速递白血病

博舒替尼在既往接受治疗的慢性髓性白血病患者中的疗效与安全性:BYOND 试验最终结果

Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial.
PubMed 文献 · Leukemia · 2024-08-20

BYOND 试验最终分析纳入 163 例对既往酪氨酸激酶抑制剂耐药或不耐受的慢性髓性白血病患者,接受博舒替尼 500 mg 每日一次治疗。中位随访 47.8 个月时,71.8% 和 59.7% 的可评估患者达到或维持主要分子学反应和 MR4,48 个月总生存率为 88.3%,长期不良事件与已知安全性特征一致,未发现新的安全性问题。

要点

  • 博舒替尼 500 mg 每日一次治疗既往治疗失败的慢性髓性白血病,71.8% 可评估患者达到或维持 MMR。
  • 36 个月维持 MMR 和 MR4 的 Kaplan-Meier 概率分别为 87.2% 和 80.7%。

核心结论

  • 博舒替尼在既往接受治疗的慢性髓性白血病患者中显示出疗效,且长期安全性与其已知特征一致,未发现新的安全性问题。

研究设计与样本

  • 4 期 BYOND 试验最终分析,163 例对既往酪氨酸激酶抑制剂耐药或不耐受的慢性髓性白血病患者接受博舒替尼治疗,起始剂量 500 mg 每日一次。

主要发现

  • 研究完成时(中位随访 47.8 个月),48.1%(75/156)的费城染色体阳性慢性期慢性髓性白血病患者仍在接受治疗。
  • 可评估患者中,71.8%(95% CI 63.9-78.9)达到或维持主要分子学反应,59.7%(95% CI 51.4-67.7)达到或维持 MR4。
  • 36 个月维持主要分子学反应和 MR4 的 Kaplan-Meier 概率分别为 87.2%(95% CI 78.0-92.7)和 80.7%(95% CI 69.4-88.1)。
  • 48 个月 Kaplan-Meier 总生存率为 88.3%(95% CI 81.8-92.6),共 17 例死亡,其中 2 例被认为与慢性髓性白血病相关。
  • 长期不良事件与博舒替尼已知安全性特征一致,未发现新的安全性问题;通过减量管理不良事件可维持疗效并改善耐受性。

临床怎么用

  • 这些结果支持在既往接受治疗的慢性髓性白血病患者中使用博舒替尼。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This final analysis from the phase 4 BYOND trial reports outcomes with bosutinib in patients with previously treated chronic myeloid leukemia (CML); 163 patients with CML resistant/intolerant to previous tyrosine kinase inhibitors received bosutinib (starting dose: 500 mg QD). At study completion (median follow-up, 47.8 months), 48.1% (n = 75/156) of patients with Philadelphia chromosome-positive chronic phase CML were still receiving treatment. Among evaluable patients, 71.8% (95% CI, 63.9-78.9) and 59.7% (95% CI, 51.4-67.7) attained or maintained major molecular response (MMR) and molecular response (MR)4, respectively, at any time on treatment. The majority of patients achieved a deeper molecular response relative to baseline while on bosutinib. Kaplan-Meier probabilities (95% CI) of maintaining MMR and MR4 at 36 months were 87.2% (78.0-92.7) and 80.7% (69.4-88.1), respectively. At 48 months, the Kaplan-Meier overall survival rate was 88.3% (95% CI, 81.8-92.6); there were 17 deaths, including 2 that were considered CML related. Long-term adverse events (AEs) were consistent with the known safety profile of bosutinib, and no new safety issues were identified. The management of AEs through dose reduction maintained efficacy while improving tolerability. These results support the use of bosutinib in patients with previously treated CML.ClinicalTrials.gov, NCT02228382.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Gambacorti-Passerini C, Brümmendorf TH, Abruzzese E, et al. Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial. Leukemia. 2024. PMID: 39164407. doi:10.1038/s41375-024-02372-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。